期刊
CELL
卷 168, 期 4, 页码 724-740出版社
CELL PRESS
DOI: 10.1016/j.cell.2017.01.016
关键词
-
资金
- NIH [P50GM081879, R01 CA196277, 5R01CA120409]
- Parker Institute for Cancer Immunotherapy
- Howard Hughes Medical Institute
Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can serve as a powerful new class of cancer therapeutics. Clinical experience has helped to define the major challenges that must be met to make engineered T cells a reliable, safe, and effective platform that can be deployed against a broad range of tumors. The emergence of synthetic biology approaches for cellular engineering is providing us with a broadly expanded set of tools for programming immune cells. We discuss how these tools could be used to design the next generation of smart T cell precision therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据